PEPG (PepGen) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PepGen FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PepGen's Free Cash Flow for the three months ended in Sep. 2024 was $-24.20 Mil. PepGen's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, PepGen's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, PepGen's current FCF Yield % is -47.03%.

The historical rank and industry rank for PepGen's FCF Margin % or its related term are showing as below:

PEPG's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

PepGen FCF Margin % Historical Data

The historical data trend for PepGen's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PepGen FCF Margin % Chart

PepGen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

PepGen Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of PepGen's FCF Margin %

For the Biotechnology subindustry, PepGen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PepGen's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PepGen's FCF Margin % falls into.

PepGen FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PepGen's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-71.596	/	0
	=	%

PepGen's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-24.197	/	0
	=	%

PepGen FCF Margin % Related Terms

Thank you for viewing the detailed overview of PepGen's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

PepGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118

Website

https://www.pepgen.com

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Executives

Michelle L Mellion	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James G Mcarthur	director, officer: President and CEO	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton	director	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C)	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Noel Donnelly	officer: Chief Financial Officer	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p.	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p.	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017